Previous 10 | Next 10 |
ConforMIS (CFMS): Q1 GAAP EPS of -$0.09 misses by $0.02.Revenue of $13.84M (-16.0% Y/Y) beats by $0.06M.Press Release For further details see: ConforMIS EPS misses by $0.02, beats on revenue
BILLERICA, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2021. First Quarter 2021 ...
3 Penny Stocks That Investors Can’t Get Enough Of The potential with penny stocks is largely unmatched by any other securities. This is not to say that all penny stocks have value, however, the large intraday fluctuations we see are not common amongst blue chips. For this rea...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the end of the week and there’s just one more day of trading to cover before we all enjoy the weekend. But before that, we’ve still got trading to do and that means looking over the pre-market move...
Conformis (CFMS) has received the FDA’s 510(k) clearance for patient-specific instrumentation (“PSI”) developed in partnership with Howmedica Osteonics, a subsidiary of Stryker Corporation (SYK). The PSI system is designed for use with Stryker’s Triathlon...
BILLERICA, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received 510(k) clearance by the U.S. Food and Drug Administration for patient-specific instrumentation (“PSI”) developed by the Company under its License Agreement and D...
Conformis (CFMS) enters into a license agreement with Paragon 28, granting Paragon 28 the use of patient-specific instruments with off-the-shelf implants in Paragon 28’s APEX 3D™ Total Ankle Replacement System.“We are pleased to reach this agreement with Paragon...
BILLERICA, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a license agreement with Paragon 28, Inc., granting Paragon 28 a non-exclusive license under a subset of Conformis’ U.S. patents for the use of patient-specific...
BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time. Mark Augusti, CEO, ...
Are These Penny Stocks On Your “Buy” Or “Avoid” List This Week? We’re at the start of a brand new week and a whole new list of penny stocks to watch. One of the popular places that retail traders are searching is on Reddit. The social media discuss...
News, Short Squeeze, Breakout and More Instantly...
BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the mark...
BILLERICA, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced results of a published study that investigated the characteristic shapes of knees to see if typica...
BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will part...